Official Title: PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN and Young Adults
https://www.clinicaltrials.gov/ct2/show/NCT04816643
Estimated Study Completion Date : June 18, 2024
Experimental: High-Dose, ≥6 Months to <2 Years
High-Dose, (30mcg), 2 doses 21 days apart
6 months to two years old; sick